CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate to Severe AD and PN in the European Union
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization for nemolizumab (Nemluvio. Galderma) for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment […]